Clinical trial
Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia
NCT00142181 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00142181 |
|---|---|
| Title | Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia |
| Official title | Phase II Study of Campath-1H in Patients With Lymphoplasmacytic Lymphoma (Waldenstrom's Macroglobulinemia) |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Brigham and Women's Hospital Beth Israel Deaconess Medical Center Massachusetts General Hospital Bayer Industry University of California, Los Angeles Northwestern University Arizona Oncology… |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoplasmacytic Lymphoma, Waldenstrom's Macroglobulinemia |
| Intervention type | Drug |
| Interventions | Campath-1H |
| Enrollment | 27 |
| Start date | Mar 1, 2003 |
| Primary completion | Oct 1, 2005 |
| Completion | Jun 1, 2008 |
| First posted | Sep 2, 2005 |
| Last update posted | Dec 21, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: